Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, is scheduled to present a poster demonstrating the clinical benefits of its lead commercial product, Excellagen®, at The Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting to be held May 1-5, 2013, in Denver, Colorado.
Authored by Steven Smith, M.D., Mohs surgeon, of Wellesley, Mass, the presentation titled “Accelerated Granulation and Healing of Problematic Post-Surgical Wounds with Formulated Collagen Gel 2.6%” will be presented by Lois Chandler, Ph.D., Cardium’s vice president of Biologics Development.
As an advanced regenerative wound product, Excellagen is capable of promoting rapid granulation and complete healing in three difficult and complex post-surgical wounds, including Mohs surgery and wound dehiscence. The presentation highlights these capabilities and presents the case that Excellagen has eliminated the need for expensive secondary reconstruction and/or skilled nursing care.
The 2013 Spring SAWC/WHS meeting gives Cardium the opportunity to exhibit Excellagen’s capabilities to more than 2,000 attendees, including physicians, podiatrists, nurses, therapists, and researchers who specialize in wound management.
The poster presentation can be viewed at www.excellagen.com/meetings-and-publications.html.
For more information visit www.cardiumthx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, April 30, 2013
GlobalWise Investments, Inc. (GWIV) CEO to Present at Taglich Brothers 10th Annual Small Cap Equity Conference
GlobalWise Investments, an Enterprise Content Management (ECM) company operating through wholly owned subsidiary Intellinetics, today reports that company president and CEO William “BJ” Santiago is scheduled to present at the Taglich Brothers 10th Annual Small Cap Equity Conference May 7, 2013, at 9 a.m. EDT.
Immediately following the presentation, Santiago will participate in a Q&A session to provide additional information.
Taglich Brothers’ annual small-cap conference features companies from every industry within the microcap segment of the market. The conference will take place at the New York Athletic Club, New York City. To request additional information or to register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com.
Taglich Brothers is a full-service broker dealer focused exclusively on microcap companies. The company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking, and comprehensive research coverage to the investment community.
GlobalWise Investments, via its wholly owned subsidiary Intellinetics, is a Columbus-based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file, or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet, or smartphone from anywhere in the world.
For additional information, please visit www.GlobalWiseInvestments.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Immediately following the presentation, Santiago will participate in a Q&A session to provide additional information.
Taglich Brothers’ annual small-cap conference features companies from every industry within the microcap segment of the market. The conference will take place at the New York Athletic Club, New York City. To request additional information or to register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com.
Taglich Brothers is a full-service broker dealer focused exclusively on microcap companies. The company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking, and comprehensive research coverage to the investment community.
GlobalWise Investments, via its wholly owned subsidiary Intellinetics, is a Columbus-based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file, or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet, or smartphone from anywhere in the world.
For additional information, please visit www.GlobalWiseInvestments.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Gevo, Inc. (GEVO) Awarded 10th Patent in its Biocatalyst Portfolio
Gevo, a renewable chemicals and next-generation biofuels company, today reported that it has received a new patent from the U.S. Patent Office covering the company’s foundational methods for producing low-cost isobutanol at commercially relevant titer, productivity, and yields.
The ‘374 Patent protects the company’s strategy of converting existing ethanol plants into bio-refineries to make isobutanol, a naturally occurring four-carbon alcohol.
“This is a milestone achievement toward our goal of making commercial isobutanol a reality,” Brett Lund, Gevo’s executive vice president and general counsel stated in the press release. “This patent significantly strengthens Gevo’s intellectual property position and reinforces our unmatched ability to obtain dramatic improvements in commercially-viable isobutanol production. We will continue to take the steps necessary to protect and maintain the integrity of our industry-leading technology.”
This is the tenth U.S. patent granted to Gevo within its biocatalyst portfolio. Gevo’s comprehensive patent portfolio includes more than 450 patents and patent applications.
Gevo is slated to release its first-quarter financial results today after market close. Analysts expect the company to report a quarterly loss of $0.40 per share on revenues of $900,000.
For more information, visit www.gevo.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The ‘374 Patent protects the company’s strategy of converting existing ethanol plants into bio-refineries to make isobutanol, a naturally occurring four-carbon alcohol.
“This is a milestone achievement toward our goal of making commercial isobutanol a reality,” Brett Lund, Gevo’s executive vice president and general counsel stated in the press release. “This patent significantly strengthens Gevo’s intellectual property position and reinforces our unmatched ability to obtain dramatic improvements in commercially-viable isobutanol production. We will continue to take the steps necessary to protect and maintain the integrity of our industry-leading technology.”
This is the tenth U.S. patent granted to Gevo within its biocatalyst portfolio. Gevo’s comprehensive patent portfolio includes more than 450 patents and patent applications.
Gevo is slated to release its first-quarter financial results today after market close. Analysts expect the company to report a quarterly loss of $0.40 per share on revenues of $900,000.
For more information, visit www.gevo.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
ZBB Energy Corp. (ZBB) Ships ZBB EnerStore to Resort in French Polynesia
ZBB Energy designs, develops, and manufactures advanced energy storage, power electronic systems, and engineered custom and semi-custom products targeted at the growing global need for distributed renewable energy, energy efficiency, power quality, and grid modernization.
The company today announced it has shipped a previously reported order from Pacific Beachcomber to supply a 2,000 kilowatt ZBB EnerStore system, including 40 ZBB EnerStore modules. The order went to Pacific Beachcomber’s Brando Resort, a luxury eco-resort located in French Polynesia. Some of the revenue from the sale will be recognized in the company’s Q3/13, with the remainder recognized during Q1/14.
The EnerStore system will be a key component of the resort’s electrical system. Its electrical supply will include a mix of renewable energy sources, including an 896 kilowatt array of photovoltaic panels and generators that use sustainable biofuels made from locally sourced coconut oil. The resort will be fully self-sustaining and is expected to be the first LEED (Leadership in Energy and Environmental Design) platinum (the highest rating) certified destination in the world.
This largest island microgrid shipment to date for ZBB Energy demonstrates its leadership position in the microgrid market. ZBB Energy’s technology allows the resort and other customers to minimize the amount of fuel consumed by utilizing generators for back-up purposes only when stored photovoltaic energy is not sufficient enough to meet overnight demand.
For additional information about ZBB Energy and its technology, please visit www.zbbenergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The company today announced it has shipped a previously reported order from Pacific Beachcomber to supply a 2,000 kilowatt ZBB EnerStore system, including 40 ZBB EnerStore modules. The order went to Pacific Beachcomber’s Brando Resort, a luxury eco-resort located in French Polynesia. Some of the revenue from the sale will be recognized in the company’s Q3/13, with the remainder recognized during Q1/14.
The EnerStore system will be a key component of the resort’s electrical system. Its electrical supply will include a mix of renewable energy sources, including an 896 kilowatt array of photovoltaic panels and generators that use sustainable biofuels made from locally sourced coconut oil. The resort will be fully self-sustaining and is expected to be the first LEED (Leadership in Energy and Environmental Design) platinum (the highest rating) certified destination in the world.
This largest island microgrid shipment to date for ZBB Energy demonstrates its leadership position in the microgrid market. ZBB Energy’s technology allows the resort and other customers to minimize the amount of fuel consumed by utilizing generators for back-up purposes only when stored photovoltaic energy is not sufficient enough to meet overnight demand.
For additional information about ZBB Energy and its technology, please visit www.zbbenergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VentriPoint Diagnostics Ltd. (VPTDF) Receives Expanded License from Health Canada
Today, VentriPoint Diagnostics reported receiving an expanded license from Health Canada that allows the company to sell the VMS™ heart analysis system for clinical use in Canada. The expansion was for the NRV™ application for the analysis of 2-D ultrasound images for patients with non-specific heart disease. The NRV™ application will enable healthcare providers to rapidly and accurately assess the status of the right ventricle in all patients that do not have significant congenital heart defects or pulmonary hypertension, yet may have a variety of other conditions.
VentriPoint’s VMS-2DE™ heart analysis system will be used in conjunction with the NRV™ database for patients where knowledge of the function of the right heart would be useful in assessing the overall heart function and optimally treat the patient. Heart disease and stroke costs the Canadian economy more than $20.9 billion every year in physician services, hospital costs, lost wages, and decreased productivity (Conference Board of Canada, 2010). It is estimated that there are 1.5 million Canadians living with heart disease and about 10% of them die each year. There are also 300,000 hospitalizations for heart failure each year and this accounts for 17% of all hospitalizations.
The addition of the NRV™ application to the VMS™ heart analysis systems will provide a direct avenue for clinicians to better evaluate and care for these individuals. VentriPoint believes that the NRV™ application can also be used to provide a reference baseline study for patients at risk for developing right heart dysfunction and would benefit from frequent monitoring.
The VMS-2DE™ is approved for clinical use in Europe and Canada and is available for investigational use only in the United States.
VentriPoint today also corrected a press release from last week. In conjunction with the final closing of the offering announced March 1, 2013, VentriPoint paid cash commissions of $10,296 and issued 102,960 agent’s options (“Agent’s Options”). As a result of the two closings, VentriPoint raised gross proceeds of $933,700 and paid total cash commissions of $26,776 and issued 267,760 Agent’s Options.
Each Agent’s Option is exercisable into one Common Share for a period of 18 months from the date of issuance at a price of $0.10 per Common Share. All securities issued pursuant to the Offering are subject to a four-month hold period pursuant to applicable securities legislation. The proceeds made available through the sale of Units will be used for the general working capital needs of the company.
For more information, visit www.ventripoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VentriPoint’s VMS-2DE™ heart analysis system will be used in conjunction with the NRV™ database for patients where knowledge of the function of the right heart would be useful in assessing the overall heart function and optimally treat the patient. Heart disease and stroke costs the Canadian economy more than $20.9 billion every year in physician services, hospital costs, lost wages, and decreased productivity (Conference Board of Canada, 2010). It is estimated that there are 1.5 million Canadians living with heart disease and about 10% of them die each year. There are also 300,000 hospitalizations for heart failure each year and this accounts for 17% of all hospitalizations.
The addition of the NRV™ application to the VMS™ heart analysis systems will provide a direct avenue for clinicians to better evaluate and care for these individuals. VentriPoint believes that the NRV™ application can also be used to provide a reference baseline study for patients at risk for developing right heart dysfunction and would benefit from frequent monitoring.
The VMS-2DE™ is approved for clinical use in Europe and Canada and is available for investigational use only in the United States.
VentriPoint today also corrected a press release from last week. In conjunction with the final closing of the offering announced March 1, 2013, VentriPoint paid cash commissions of $10,296 and issued 102,960 agent’s options (“Agent’s Options”). As a result of the two closings, VentriPoint raised gross proceeds of $933,700 and paid total cash commissions of $26,776 and issued 267,760 Agent’s Options.
Each Agent’s Option is exercisable into one Common Share for a period of 18 months from the date of issuance at a price of $0.10 per Common Share. All securities issued pursuant to the Offering are subject to a four-month hold period pursuant to applicable securities legislation. The proceeds made available through the sale of Units will be used for the general working capital needs of the company.
For more information, visit www.ventripoint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Rainbow Coral Corp. (RBCC) Prepares for Revolution in Pharmaceutical and Insurance Industries
The rapid growth of personalized genomic medicine is poised to radically change not only the way that pharmaceutical companies develop drugs, but the way insurance companies administer healthcare plans. Acknowledging the increasing momentum, Rainbow Coral today told investors that it is forging ahead with plans for new partnerships in both genetic testing and companion diagnostics.
PricewaterhouseCoopers predicts that the personalized medicine sector could grow to as much as $452 billion by 2015. One of the driving forces behind this expansion is the inefficient way in which drugs are currently produced. Because insurance companies try to avoid paying for drugs that don’t work, pharmaceutical companies are beginning to use data derived from personalized genome testing to indicate which drugs will work for specific patients—making a stronger case for payer reimbursement.
In March, MedCity News reported that over half of pharmaceutical giant AstraZeneca’s drug pipeline is being developed as personalized medicine. RBCC believes that percentage will continue to rise as insurance companies begin to mandate genetic testing for patients before agreeing to pay for new prescriptions.
“It changes the business model completely,” emphasized RBCC CEO Patrick Brown. “Personalized medicine, including genetic testing and companion diagnostics, is already helping to develop pharmaceuticals personalized to patients. Soon, their healthcare plans will be personalized, too.”
In order to secure a growing share of a personalized medicine market that is becoming increasingly lucrative, the company is seeking out new innovations and technologies that promise to dramatically improve patient outcomes and reduce healthcare costs. For more information on Rainbow BioSciences’ personalized medicine initiatives, visit www.rainbowbiosciences.com/investors.html.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
PricewaterhouseCoopers predicts that the personalized medicine sector could grow to as much as $452 billion by 2015. One of the driving forces behind this expansion is the inefficient way in which drugs are currently produced. Because insurance companies try to avoid paying for drugs that don’t work, pharmaceutical companies are beginning to use data derived from personalized genome testing to indicate which drugs will work for specific patients—making a stronger case for payer reimbursement.
In March, MedCity News reported that over half of pharmaceutical giant AstraZeneca’s drug pipeline is being developed as personalized medicine. RBCC believes that percentage will continue to rise as insurance companies begin to mandate genetic testing for patients before agreeing to pay for new prescriptions.
“It changes the business model completely,” emphasized RBCC CEO Patrick Brown. “Personalized medicine, including genetic testing and companion diagnostics, is already helping to develop pharmaceuticals personalized to patients. Soon, their healthcare plans will be personalized, too.”
In order to secure a growing share of a personalized medicine market that is becoming increasingly lucrative, the company is seeking out new innovations and technologies that promise to dramatically improve patient outcomes and reduce healthcare costs. For more information on Rainbow BioSciences’ personalized medicine initiatives, visit www.rainbowbiosciences.com/investors.html.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Rand Worldwide, Inc. (RWWI) Division Announces Release of Powerful, New Scan to BIM™ 2014 Software
Rand Worldwide, a prominent supplier of technology solutions to organizations with engineering design and information technology requirements worldwide, announced today that its IMAGINiT Technologies division has released its innovative Scan to BIM 2014 software. This new software enables streamlined workflows from intelligent 3D data from captured laser scans by utilizing the new Autodesk ReCap Point Cloud Engine. In addition to providing powerful new features, the new software package maintains complete compatibility with the Autodesk Revit 2014.
“By keeping our software development in lockstep with Autodesk software rollouts, we ensure customers are able to leverage every benefit that a new release offers as quickly as possible,” says Bob Heeg, executive vice president, worldwide operations, IMAGINiT Technologies. “Our commitment to the best possible customer experience and bringing new features requested by our customers are two of the key ingredients to our success with all of our software products such as Scan to BIM, IMAGINiT Clarity, IMAGINiT Utilities for Revit and more.”
Rand’s new Scan to BIM 2014 version is targeted towards architects, engineers, contractors, and surveyors to help them evolve in their interactions with point cloud data in Revit. Scan to BIM delivers expanded point cloud functionality and modeling data that can be both trusted and validated by building upon the Autodesk Revit platform. Users are capable of interacting with point clouds within Scan to BIM. This feature assists with automated recognition and placement of architectural elements such as walls and columns, as well as MEP elements such as pipes, ducts, conduit, and more.
“IMAGINiT’s Scan to BIM is a great example of our thriving Revit Platform ecosystem — we’re excited to see what they’re doing with our new ReCap technology,” says Kyle Bernhardt, Building Design Suite product line manager, Autodesk. “With BIM authoring labor representing one of the highest costs in a scan to BIM project, it’s tools like Scan to BIM that drive down the time required to author an accurate as-built BIM; it goes straight to the bottom line.”
For further information, please visit www.Imagint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“By keeping our software development in lockstep with Autodesk software rollouts, we ensure customers are able to leverage every benefit that a new release offers as quickly as possible,” says Bob Heeg, executive vice president, worldwide operations, IMAGINiT Technologies. “Our commitment to the best possible customer experience and bringing new features requested by our customers are two of the key ingredients to our success with all of our software products such as Scan to BIM, IMAGINiT Clarity, IMAGINiT Utilities for Revit and more.”
Rand’s new Scan to BIM 2014 version is targeted towards architects, engineers, contractors, and surveyors to help them evolve in their interactions with point cloud data in Revit. Scan to BIM delivers expanded point cloud functionality and modeling data that can be both trusted and validated by building upon the Autodesk Revit platform. Users are capable of interacting with point clouds within Scan to BIM. This feature assists with automated recognition and placement of architectural elements such as walls and columns, as well as MEP elements such as pipes, ducts, conduit, and more.
“IMAGINiT’s Scan to BIM is a great example of our thriving Revit Platform ecosystem — we’re excited to see what they’re doing with our new ReCap technology,” says Kyle Bernhardt, Building Design Suite product line manager, Autodesk. “With BIM authoring labor representing one of the highest costs in a scan to BIM project, it’s tools like Scan to BIM that drive down the time required to author an accurate as-built BIM; it goes straight to the bottom line.”
For further information, please visit www.Imagint.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Emisphere Technologies, Inc. (EMIS) and Novo Nordisk (NVO) Amend Development and License Agreement
Emisphere Technologies, a biopharm company, and Novo Nordisk A/S have amended their development and license agreement under which the companies are working to develop and commercialize oral formulations of Novo Nordisk’s proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere’s Eligen® technology.
Per the amendment, Novo Nordisk will pay to Emisphere $10 million as a prepayment of development milestone payments that would have otherwise been paid to Emisphere upon the initiation of phase II and phase III testing of an oral GLP-1 product by Novo Nordisk. Novo Nordisk is currently conducting phase I trials for its Oral GLP-1 product candidate.
In exchange, Novo Nordisk will receive a reduction in the rate of potential future royalty payments stemming from future sales of an oral GLP-1 product developed under the Oral GLP-1 development agreement signed in 2008.
“We highly value our long-standing relationship with Novo Nordisk,” Alan L. Rubino, president and CEO of Emisphere stated in the press release. “The accelerated milestone payment will significantly assist our efforts to expedite key growth initiatives for the company.”
Under the terms of the Oral GLP-1 development agreement, Emisphere may still receive product development and sales milestone payments as well as potential future royalty payments.
Emisphere’s broad-based drug delivery technology platform is called the Eligen® Technology – the platform uses proprietary, synthetic chemical compounds to deliver a therapeutic molecule without altering its chemical form or biological integrity.
For more information visit www.emisphere.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Per the amendment, Novo Nordisk will pay to Emisphere $10 million as a prepayment of development milestone payments that would have otherwise been paid to Emisphere upon the initiation of phase II and phase III testing of an oral GLP-1 product by Novo Nordisk. Novo Nordisk is currently conducting phase I trials for its Oral GLP-1 product candidate.
In exchange, Novo Nordisk will receive a reduction in the rate of potential future royalty payments stemming from future sales of an oral GLP-1 product developed under the Oral GLP-1 development agreement signed in 2008.
“We highly value our long-standing relationship with Novo Nordisk,” Alan L. Rubino, president and CEO of Emisphere stated in the press release. “The accelerated milestone payment will significantly assist our efforts to expedite key growth initiatives for the company.”
Under the terms of the Oral GLP-1 development agreement, Emisphere may still receive product development and sales milestone payments as well as potential future royalty payments.
Emisphere’s broad-based drug delivery technology platform is called the Eligen® Technology – the platform uses proprietary, synthetic chemical compounds to deliver a therapeutic molecule without altering its chemical form or biological integrity.
For more information visit www.emisphere.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Echelon Corp. (ELON) Announces Partnership with ITOCHU and Mitsui for Street Lighting Control System Pilots in Japan
Echelon, the world’s leading open standard energy control networking company, announced several leading Japanese cities are now piloting street lighting management systems based on technology from Echelon after witnessing the company’s successful demonstration of intelligent street lighting control in the Japanese technology city of Tsukuba in 2011. The piloted systems are configured on the open ISO/IEC 14908 standard and implemented using Echelon’s Power Line Communications (PLC) transceivers and segment controllers. ITOCHU Corporation, an Echelon partner, has installed the second phase in the city of Tsukuba. This project was accomplished in cooperation with Panasonic and Toshiba, major Japanese lighting device manufacturers.
As Echelon’s master distributor in Japan, ITOCHU also collaborated with a new market entrant, Mitsui & Company, for two pilot sites. Mitsui has installed the systems in the city of Higashi Matsushima, part of the earthquake damaged region of Tohoku, and at the campus of Hiroshima City University in the city of Hiroshima. The deployed ISO 14908 based solution supports a variety of luminaires ranging from LEDs from Toshiba and GE to Ceramic Metal Halide lights from GS Yuasa. Implementation of street light management systems further lower energy use and reduce the cost of operating the street light infrastructure.
The change-out of High Pressure Sodium (HPS) lamps to dimmable LEDs is lowering per lamp electricity consumption by more than 50% or nearly 120Kg of CO2 per year, and is expected to save approximately $240/year in places like Hiroshima, where rising Japanese prices now make it comparable to high cost Asia-Pacific locations like Australia and the Philippines. The use of the new technology allows for the setting of dimming schedules, based on weather and traffic patterns, and delivers 20% to 30% of the savings relative to just shifting from HPS to LED. The system also increases public safety by allowing all pilot lamps to be monitored from a central city location so that failures can be identified and responded to quickly.
“In addition to reducing energy costs and maintenance costs, the use of a standards-based control system allows the cities to manage life cycle procurement costs by providing them with a choice of luminaires, an expense that is often more than 80% of the cost of the project,” commented Varun Nagaraj , Senior Vice President at Echelon Corporation. “We are excited to be partnering with ITOCHU and Mitsui – two of Japan’s leading solution providers – and look forward to larger roll-outs across these cities over the next few years.”
For more information on Echelon Corporation, please visit www.echelon.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
As Echelon’s master distributor in Japan, ITOCHU also collaborated with a new market entrant, Mitsui & Company, for two pilot sites. Mitsui has installed the systems in the city of Higashi Matsushima, part of the earthquake damaged region of Tohoku, and at the campus of Hiroshima City University in the city of Hiroshima. The deployed ISO 14908 based solution supports a variety of luminaires ranging from LEDs from Toshiba and GE to Ceramic Metal Halide lights from GS Yuasa. Implementation of street light management systems further lower energy use and reduce the cost of operating the street light infrastructure.
The change-out of High Pressure Sodium (HPS) lamps to dimmable LEDs is lowering per lamp electricity consumption by more than 50% or nearly 120Kg of CO2 per year, and is expected to save approximately $240/year in places like Hiroshima, where rising Japanese prices now make it comparable to high cost Asia-Pacific locations like Australia and the Philippines. The use of the new technology allows for the setting of dimming schedules, based on weather and traffic patterns, and delivers 20% to 30% of the savings relative to just shifting from HPS to LED. The system also increases public safety by allowing all pilot lamps to be monitored from a central city location so that failures can be identified and responded to quickly.
“In addition to reducing energy costs and maintenance costs, the use of a standards-based control system allows the cities to manage life cycle procurement costs by providing them with a choice of luminaires, an expense that is often more than 80% of the cost of the project,” commented Varun Nagaraj , Senior Vice President at Echelon Corporation. “We are excited to be partnering with ITOCHU and Mitsui – two of Japan’s leading solution providers – and look forward to larger roll-outs across these cities over the next few years.”
For more information on Echelon Corporation, please visit www.echelon.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Islet Sciences, Inc. (ISLT) Announces Receipt of Japanese Patent Covering New Diabetes Medications
Biotechnology company Islet Sciences has announced the receipt of a Japanese patent for allowed claims covering new medications for diabetes.
The notice of allowed claims for Patent Application No. 2008-529208 includes the use and composition for small molecules in preventing or treating pathological inflammatory or autoimmune condition – in particular, type 1 diabetes, atherosclerosis, type 2 diabetes, disorders related to visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer’s disease.
The patent signifies an additional aspect to the value of Islet Sciences’ therapies, which represent a large market opportunity for the diabetic community and also for the company’s stakeholders. Islet Sciences’ focus is on researching, developing, and commercializing patented technologies for people with diabetes.
“We are pleased to announce this significant milestone, which clearly strengthens our global value proposition,” said Islet Sciences Chairman and CEO John Steel. “This patent provides further evidence for the value and promise of this technology to be developed for treatments for diabetes and related complications.”
A development-stage biotechnology company, Islet Sciences possesses patented technologies that are focused on infusion for individuals with insulin-dependent diabetes. Included in the company’s infusion technology are methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. Islet Sciences’ mission includes introducing commercial products that are relevant to the insulin-dependent diabetes marketplace, including diagnostics and anti-inflammatory compounds.
For more information, visit www.isletsciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The notice of allowed claims for Patent Application No. 2008-529208 includes the use and composition for small molecules in preventing or treating pathological inflammatory or autoimmune condition – in particular, type 1 diabetes, atherosclerosis, type 2 diabetes, disorders related to visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer’s disease.
The patent signifies an additional aspect to the value of Islet Sciences’ therapies, which represent a large market opportunity for the diabetic community and also for the company’s stakeholders. Islet Sciences’ focus is on researching, developing, and commercializing patented technologies for people with diabetes.
“We are pleased to announce this significant milestone, which clearly strengthens our global value proposition,” said Islet Sciences Chairman and CEO John Steel. “This patent provides further evidence for the value and promise of this technology to be developed for treatments for diabetes and related complications.”
A development-stage biotechnology company, Islet Sciences possesses patented technologies that are focused on infusion for individuals with insulin-dependent diabetes. Included in the company’s infusion technology are methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. Islet Sciences’ mission includes introducing commercial products that are relevant to the insulin-dependent diabetes marketplace, including diagnostics and anti-inflammatory compounds.
For more information, visit www.isletsciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Aristocrat Group Corp. (ASCC) Wins Patent Approval for New Vodka Brand – Name Debut on the Horizon
The Aristocrat Group achieved a key breakthrough this week in its trek to release a new brand of ultra-premium vodka when Luxuria Brands, Aristocrat’s brand management division, received approval from the U.S. Patent and Trademark Office for the distilled spirit’s proposed name.
Luxuria Brands is now awaiting Certification of Label/Bottle Approval (COLA) from the Alcohol and Tobacco Tax and Trade Bureau (TTB) to ensure that the new spirit has been created, labeled, and marketed in compliance with federal laws and regulations. The company anticipates receiving the certification this week and will soon reveal the name of its debut vodka.
“We’re very pleased to pass another milestone in our plans to get our distilled spirits on store shelves as quickly as possible,” ASCC CEO Robert Federowicz stated in the press release. “It’s been a challenge to remain patient through this approval process, but we’re looking forward to releasing the name and bottle design of the world’s next top ultra-premium vodka as soon as we receive our COLA approval. These are exciting times for our company.”
Through Luxuria Brands, Aristocrat aims to becoming a provider of premiere luxury goods. The company is has chosen the super-premium vodka segment for its debut offering because of the segment’s considerable growth. According to industry trade group the Distilled Spirits Council (DISCUS), the vodka segment has risen 32 percent in the last two years to $1.2 billion.
For more information visit www.aristocratgroupcorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Luxuria Brands is now awaiting Certification of Label/Bottle Approval (COLA) from the Alcohol and Tobacco Tax and Trade Bureau (TTB) to ensure that the new spirit has been created, labeled, and marketed in compliance with federal laws and regulations. The company anticipates receiving the certification this week and will soon reveal the name of its debut vodka.
“We’re very pleased to pass another milestone in our plans to get our distilled spirits on store shelves as quickly as possible,” ASCC CEO Robert Federowicz stated in the press release. “It’s been a challenge to remain patient through this approval process, but we’re looking forward to releasing the name and bottle design of the world’s next top ultra-premium vodka as soon as we receive our COLA approval. These are exciting times for our company.”
Through Luxuria Brands, Aristocrat aims to becoming a provider of premiere luxury goods. The company is has chosen the super-premium vodka segment for its debut offering because of the segment’s considerable growth. According to industry trade group the Distilled Spirits Council (DISCUS), the vodka segment has risen 32 percent in the last two years to $1.2 billion.
For more information visit www.aristocratgroupcorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, April 29, 2013
GlobalWise Investments, Inc. (GWIV) and Muratec America Ink New Channel Sales Partnership
GlobalWise Investments and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on the design, implementation, and management of cloud-based Enterprise Content Management (“ECM”) systems, today announced the signing of a new channel sales partnership with Muratec America, Inc. (www.muratec.com).
Headquartered in Plano, TX, Muratec America is a U.S. based subsidiary of Muratec Machinery, Ltd., a privately held Japanese multinational corporation founded in 1935. Known throughout North and South America, Muratec America manufactures workgroup A4 (letter/legal) multifunction printing solutions and provides managed document services components. Muratec America has an experienced sales force and over 500 dealers in North America.
“Muratec America represents another fantastic channel partner to expand our growth in both the public and private sectors addressing our strategic focus in the Managed Print Services (MPS) and Managed Services industries. Muratec America already has an established document management practice, and we’re excited to earn their trust as partners. Their technological and domain expertise in document management will most likely expedite our path-to-market and establish our presence in the Managed Print Services and Managed Services industries,” commented William “BJ” Santiago, CEO of GlobalWise. “Muratec has been a proven leader in offering solutions to their distribution channel of 500 dealers throughout North America selling the Muratec line of multifunction printers. Additionally, each Muratec dealer has approximately 2,000 end-user clients who will now be offered our Intellivue™ solution, and we’re excited about this expanded reach to the market.”
“We deeply value our IT managed services and managed document services components with a laser focus on offering best-in-class solutions that enable our dealer network to sell and have a competitive advantage with their clients and trusted relationships,” said Jim D’Emidio, President of Muratec America, Inc. “It was vitally important we found the next generation of an ECM cloud-based provider who understood the mission critical and privacy needs within the copier dealer end-user client community. We were truly impressed with GlobalWise’s unique packaging of their ECM cloud-based solution and their out of the box innovative workflow ‘on-demand’ solution templates that allows our end-user clients to immediately improve on both workflow and paper efficiencies in mission critical business areas. This new ECM model is also easier for the traditional copier dealer sales representatives to sell because it’s not about features and functions but about improving business process optimization for their companies. We’re truly excited about the launch of this relationship with GlobalWise.”
For more information, visit www.globalwiseinvestments.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Headquartered in Plano, TX, Muratec America is a U.S. based subsidiary of Muratec Machinery, Ltd., a privately held Japanese multinational corporation founded in 1935. Known throughout North and South America, Muratec America manufactures workgroup A4 (letter/legal) multifunction printing solutions and provides managed document services components. Muratec America has an experienced sales force and over 500 dealers in North America.
“Muratec America represents another fantastic channel partner to expand our growth in both the public and private sectors addressing our strategic focus in the Managed Print Services (MPS) and Managed Services industries. Muratec America already has an established document management practice, and we’re excited to earn their trust as partners. Their technological and domain expertise in document management will most likely expedite our path-to-market and establish our presence in the Managed Print Services and Managed Services industries,” commented William “BJ” Santiago, CEO of GlobalWise. “Muratec has been a proven leader in offering solutions to their distribution channel of 500 dealers throughout North America selling the Muratec line of multifunction printers. Additionally, each Muratec dealer has approximately 2,000 end-user clients who will now be offered our Intellivue™ solution, and we’re excited about this expanded reach to the market.”
“We deeply value our IT managed services and managed document services components with a laser focus on offering best-in-class solutions that enable our dealer network to sell and have a competitive advantage with their clients and trusted relationships,” said Jim D’Emidio, President of Muratec America, Inc. “It was vitally important we found the next generation of an ECM cloud-based provider who understood the mission critical and privacy needs within the copier dealer end-user client community. We were truly impressed with GlobalWise’s unique packaging of their ECM cloud-based solution and their out of the box innovative workflow ‘on-demand’ solution templates that allows our end-user clients to immediately improve on both workflow and paper efficiencies in mission critical business areas. This new ECM model is also easier for the traditional copier dealer sales representatives to sell because it’s not about features and functions but about improving business process optimization for their companies. We’re truly excited about the launch of this relationship with GlobalWise.”
For more information, visit www.globalwiseinvestments.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
India Globalization Capital, Inc. (IGC) Doubles-Down On Chinese Steel, Opens New Hub on Border with Mongolia to Source Supply
India Globalization Capital, which is diversified into related mining, materials, infrastructure, and logistics areas via its family of 100%-owned subsidiaries, reported good news today out of their HK Ironman unit (which owns 95% of Linxi HeFei Economic & Trade Co., Ltd., aka PRC Ironman) that runs an iron ore beneficiation plant on 0.85 square miles of hills outside Chifeng, with ore deposits in the neighborhood of 3M tons, as a new and key shipping hub has been established by the company on the Mongolia-China border.
CEO of the Bethesda, Maryland-based IGC, Ram Mukunda, looked back with pride on six strenuous months of planning, negotiations, and prep work culminating in today’s announcement and noted how the company was already putting their new limb to the test with a 300 ton shipment. Mukunda projected a rapid up-scaling of throughput after this test delivery is completed in the next week or so, with a leading target set between 8k and 12k tons per month, a considerable beefing-up of the company’s overall throughout capacity.
This new hub is part of IGC’s long-term strategic growth plan and will serve from an ideal location, the vital role of both a sourcing point for the company’s beneficiation plants and an output node for the many, many iron ore customers IGC has access to in China. A total portrait of this new capacity shows how the ideally-positioned hub can not only deliver a variety of grades of ore, but do so expeditiously and from sourcing points which were virtually nonexistent only a handful of years ago.
Looking back to around 2008, at the time when PRC Ironman was founded, there were almost no real sources of iron ore exports in Mongolia. The meteoric rise since then by IGC, driven by strong demand for iron ore, has mirrored the expansion of resource production capacity in Mongolia, with some 5.75M tons coming out of the country last year, up a whopping 61% over 2011 alone (according to top regional investment analysis firm Mongolia Asset Management).
Even now, the demand from Chinese steel producers for quality iron ore is immense and IGC is intent on capturing the premium profitability metrics here by continuing to open up Mongolia as a resource supplier. This shipping hub is a necessary piece of the puzzle for IGC’s long-term delivery and refining aspirations, investors will want to keep an eye on the company in the next few weeks for more news about the hub once the initial test shipment is finished.
To get a closer look at India Globalization Capital, visit www.IndiaGlobalCap.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
CEO of the Bethesda, Maryland-based IGC, Ram Mukunda, looked back with pride on six strenuous months of planning, negotiations, and prep work culminating in today’s announcement and noted how the company was already putting their new limb to the test with a 300 ton shipment. Mukunda projected a rapid up-scaling of throughput after this test delivery is completed in the next week or so, with a leading target set between 8k and 12k tons per month, a considerable beefing-up of the company’s overall throughout capacity.
This new hub is part of IGC’s long-term strategic growth plan and will serve from an ideal location, the vital role of both a sourcing point for the company’s beneficiation plants and an output node for the many, many iron ore customers IGC has access to in China. A total portrait of this new capacity shows how the ideally-positioned hub can not only deliver a variety of grades of ore, but do so expeditiously and from sourcing points which were virtually nonexistent only a handful of years ago.
Looking back to around 2008, at the time when PRC Ironman was founded, there were almost no real sources of iron ore exports in Mongolia. The meteoric rise since then by IGC, driven by strong demand for iron ore, has mirrored the expansion of resource production capacity in Mongolia, with some 5.75M tons coming out of the country last year, up a whopping 61% over 2011 alone (according to top regional investment analysis firm Mongolia Asset Management).
Even now, the demand from Chinese steel producers for quality iron ore is immense and IGC is intent on capturing the premium profitability metrics here by continuing to open up Mongolia as a resource supplier. This shipping hub is a necessary piece of the puzzle for IGC’s long-term delivery and refining aspirations, investors will want to keep an eye on the company in the next few weeks for more news about the hub once the initial test shipment is finished.
To get a closer look at India Globalization Capital, visit www.IndiaGlobalCap.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VistaGen Therapeutics, Inc. (VSTA) Turns a Billion Dollar Problem into a One-Of-A-Kind Opportunity
The strategy of VistaGen Therapeutics, a California based stem-cell technology company, is primed to drive rapid growth because of its unique structure. VistaGen is a developer of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates. It provides a distinctive way of determining potential drug toxicity well before the time and expense involved in performing animal or human trials.
The history of the pharmaceutical industry is one littered with drug candidates that were developed, and sometimes even released to the public, only to discover later that there were heart or liver toxicity issues. These drugs were then often shelved, resulting in a massive loss of invested time and money for the pharmaceutical company involved. For drug companies around the world it’s a major problem. However, for VistaGen it represents a major opportunity.
VistaGen’s plan is to use their proprietary Human Clinical Trials in a Test Tube stem cell based platform, a novel bioassay system that provides toxicity testing right in the laboratory, to build a portfolio of drug rescue variants from once-promising but discontinued drug candidates. Considering the fact that development costs for a new drug can easily exceed $1 billion, VistaGen sees these shelved drugs as a veritable diamond mine which it now has the means to tap. It’s like having someone run a 20-mile marathon for you, and then letting you step in near the end to cross the finish line.
Specifically, VistaGen believes each lead drug rescue variant will have the potential to be a viable new drug candidate in which VistaGen can have significant economic participation rights, such as up-front and development milestone payments and royalties on commercial sales. Its valuable technology also sets the company up as a potential takeover target.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The history of the pharmaceutical industry is one littered with drug candidates that were developed, and sometimes even released to the public, only to discover later that there were heart or liver toxicity issues. These drugs were then often shelved, resulting in a massive loss of invested time and money for the pharmaceutical company involved. For drug companies around the world it’s a major problem. However, for VistaGen it represents a major opportunity.
VistaGen’s plan is to use their proprietary Human Clinical Trials in a Test Tube stem cell based platform, a novel bioassay system that provides toxicity testing right in the laboratory, to build a portfolio of drug rescue variants from once-promising but discontinued drug candidates. Considering the fact that development costs for a new drug can easily exceed $1 billion, VistaGen sees these shelved drugs as a veritable diamond mine which it now has the means to tap. It’s like having someone run a 20-mile marathon for you, and then letting you step in near the end to cross the finish line.
Specifically, VistaGen believes each lead drug rescue variant will have the potential to be a viable new drug candidate in which VistaGen can have significant economic participation rights, such as up-front and development milestone payments and royalties on commercial sales. Its valuable technology also sets the company up as a potential takeover target.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Aristocrat Group Corp. (ASCC) Moves to Next Level with Luxuria Brands
The Aristocrat Group is a Florida based company focused on developing globalized luxury consumer goods brands, with an initial focus on premium distilled spirits such as the growing world market for premium vodka. The company is all about commercializing and innovating products with a proven following. With the recent creation of their new subsidiary, Luxuria Brands, focused on brand management and sustainability, they feel they are taking the process to a new level. Luxuria will strategize, develop, and market brands using strategic cross-cultural branding initiatives designed to engage businesses and consumers alike.
Initially, Luxuria Brands will be working on creating brand identities and loyalty within the distilled spirits sector, and has already identified manufacturing partners to develop, bottle, and distribute a unique line of vodka and vodka based beverages. The market for vodka is massive and growing, both in the U.S. and worldwide, and premium priced beverages are generating premium returns for businesses and investors.
Luxuria is taking advantage of this global opportunity by identifying promising products and applying creative promotional strategies to place the company in a leadership position:
• Develop bold opportunities to reach a broader audience through the synergies of promotion and entertainment, building “sharable” brands. 50% of the world’s population is under the age of 30, creating opportunity for new brand loyalties to emerge.
• Engage consumers with messaging and packaging that differentiates a “standardized” product while developing a strong, consistent brand identity. For example, approximately 60% of people in bars have not decided what drink they want until after they get there.
• Redefine the methods premium spirit brands use to reach consumers, and monetize the power shift of social empowerment as a brand builder. In the U.S. alone, 67% of adults use one of the popular social media sites with little ethnic disparity.
For additional information, visit www.AristocratGroupCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Initially, Luxuria Brands will be working on creating brand identities and loyalty within the distilled spirits sector, and has already identified manufacturing partners to develop, bottle, and distribute a unique line of vodka and vodka based beverages. The market for vodka is massive and growing, both in the U.S. and worldwide, and premium priced beverages are generating premium returns for businesses and investors.
Luxuria is taking advantage of this global opportunity by identifying promising products and applying creative promotional strategies to place the company in a leadership position:
• Develop bold opportunities to reach a broader audience through the synergies of promotion and entertainment, building “sharable” brands. 50% of the world’s population is under the age of 30, creating opportunity for new brand loyalties to emerge.
• Engage consumers with messaging and packaging that differentiates a “standardized” product while developing a strong, consistent brand identity. For example, approximately 60% of people in bars have not decided what drink they want until after they get there.
• Redefine the methods premium spirit brands use to reach consumers, and monetize the power shift of social empowerment as a brand builder. In the U.S. alone, 67% of adults use one of the popular social media sites with little ethnic disparity.
For additional information, visit www.AristocratGroupCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Real Goods Solar, Inc. (RSOL) Provides Solar Power for Pennsylvania School
RGS Energy, the commercial and utility division of Real Goods Solar, announced that they will install 1.1 mw of solar power at Church Farm School in Exton, Pennsylvania, helping them save hundreds of thousands of dollars each year in electric costs.
The $3.2 million operation was paid in part by a $1.19 million grant from the Pennsylvania Department of Environmental Protection. Not only does this operation seek to lower the costs of energy at the school, but it also helps lower the school’s greenhouse emissions. The remainder of the cost is funded through a power purchase agreement (PPA) with Smart Energy Capital (SEC).
“Church Farm School’s solar installation sets a standard for other schools and businesses to follow,” says RGS Energy General Manager Tim Seamans. “Solar energy is a truly cost effective way to reduce operating costs while reducing environmental impact.”
The head of the school sees more than one benefit to the installation.
“Our students have a real life laboratory to explore and learn more about their energy future,” said Head of School, The Reverend Edmund K. Sherrill. “That we reduce our energy costs along the way is an added bonus since it will redirect dollars spent on energy to our school’s mission that provides such a great education at little to no cost.”
The photovoltaic solar system, comprised of over 3,500 solar panels, is expected to produce nearly 1.5 million kWh of electricity per year. The clean power generated from the ground mount system, installed on five acres of school land, will supply approximately 75% of the school’s electrical needs and provide Church Farm students and faculty an on-site source of renewable energy and exposure to best practices in sustainability.
For more information, visit www.RealGoodsSolar.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The $3.2 million operation was paid in part by a $1.19 million grant from the Pennsylvania Department of Environmental Protection. Not only does this operation seek to lower the costs of energy at the school, but it also helps lower the school’s greenhouse emissions. The remainder of the cost is funded through a power purchase agreement (PPA) with Smart Energy Capital (SEC).
“Church Farm School’s solar installation sets a standard for other schools and businesses to follow,” says RGS Energy General Manager Tim Seamans. “Solar energy is a truly cost effective way to reduce operating costs while reducing environmental impact.”
The head of the school sees more than one benefit to the installation.
“Our students have a real life laboratory to explore and learn more about their energy future,” said Head of School, The Reverend Edmund K. Sherrill. “That we reduce our energy costs along the way is an added bonus since it will redirect dollars spent on energy to our school’s mission that provides such a great education at little to no cost.”
The photovoltaic solar system, comprised of over 3,500 solar panels, is expected to produce nearly 1.5 million kWh of electricity per year. The clean power generated from the ground mount system, installed on five acres of school land, will supply approximately 75% of the school’s electrical needs and provide Church Farm students and faculty an on-site source of renewable energy and exposure to best practices in sustainability.
For more information, visit www.RealGoodsSolar.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
University of Kansas Study Highlights Voice Assist, Inc. (VSST) Hands-Free Mobile Solution to Distracted Driving
Voice Assist provides mobile speech and hands-free communication solutions applicable for smart phones, tablet PCs, and other network-connected devices. The company recently highlighted the results of a recent study on distracted driving, conducted by the University of Kansas, School of Architecture, Design & Planning.
An alarming increase in the number of automobile crashes attributed to distracted drivers has spurred legislative action to curb the use of electronics while driving. Many cities have already implemented laws against driving and texting, as well as laws against cell phone use unless it is a hands-free connection.
In correlation, the University of Kansas in its own effort to find a solution to distracted driving has performed in-depth studies and research on hands-free driving technologies and user interfaces.
“Our study of the product and services offered by Voice Assist positions it as one, if not the only company that offers a logical and effective system that helps curtail driver distraction,” Professor Gregory Thomas, design director for the Center for Design Research at the University of Kansas said in a statement. “With its ability to handle texting, calls or email it does so with ease and clarity from any phone or device. To add to its features, it can also provide ‘Live Assist,’ a concierge service, which enables a live person to search for the questions you have without searching through layers of navigational screens. Conducting conversations while driving should always be limited but we feel Voice Assist provides a good product and service that helps with visual diversion associated with many accidents.”
The University of Kansas conducted its test using the fully integrated hands-free speakerphone solution that includes Voice Assist’s patent pending hands-free interface and a Jabra Freeway, which can be clipped onto the sun visor in any car.
Michael Metcalf, CEO of Voice Assist explained how the company’s technology differs from big name technologies.
“Unlike Apple SIRI or Google now, Voice Assist focused on a hands-free solution with a continuous voice connection to let drivers send and receive text messages and e-mails or use Twitter or Facebook or make multiple calls without pressing a button to complete each task. We are very pleased that the University of Kansas recognized our patent pending hands-free interface designed to encourage safer driving, especially since April is national distracted driving awareness month,” he said in the press release.
In honor of national distracted driving awareness month, Voice Assist is offering a discounted price for the combined solution.
For more information, visit www.voiceassist.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
An alarming increase in the number of automobile crashes attributed to distracted drivers has spurred legislative action to curb the use of electronics while driving. Many cities have already implemented laws against driving and texting, as well as laws against cell phone use unless it is a hands-free connection.
In correlation, the University of Kansas in its own effort to find a solution to distracted driving has performed in-depth studies and research on hands-free driving technologies and user interfaces.
“Our study of the product and services offered by Voice Assist positions it as one, if not the only company that offers a logical and effective system that helps curtail driver distraction,” Professor Gregory Thomas, design director for the Center for Design Research at the University of Kansas said in a statement. “With its ability to handle texting, calls or email it does so with ease and clarity from any phone or device. To add to its features, it can also provide ‘Live Assist,’ a concierge service, which enables a live person to search for the questions you have without searching through layers of navigational screens. Conducting conversations while driving should always be limited but we feel Voice Assist provides a good product and service that helps with visual diversion associated with many accidents.”
The University of Kansas conducted its test using the fully integrated hands-free speakerphone solution that includes Voice Assist’s patent pending hands-free interface and a Jabra Freeway, which can be clipped onto the sun visor in any car.
Michael Metcalf, CEO of Voice Assist explained how the company’s technology differs from big name technologies.
“Unlike Apple SIRI or Google now, Voice Assist focused on a hands-free solution with a continuous voice connection to let drivers send and receive text messages and e-mails or use Twitter or Facebook or make multiple calls without pressing a button to complete each task. We are very pleased that the University of Kansas recognized our patent pending hands-free interface designed to encourage safer driving, especially since April is national distracted driving awareness month,” he said in the press release.
In honor of national distracted driving awareness month, Voice Assist is offering a discounted price for the combined solution.
For more information, visit www.voiceassist.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Stem Cell Corp. (ISCO) Gives Lifeline Skin Care the Winning Edge
On the Lifeline Skin Care website (www.LifelineSkinCare.com) it says “Someday, stem cells will change the world. Today, stem cells will change your skin.” Lifeline Skin Care, a subsidiary of International Stem Cell Corp., produces stem cell based skin care products, leveraging technology only available through its association with ISCO. Although the application of stem cells and their regeneration properties to skin rejuvenation has been heavily popularized, Lifeline Skin Care’s offerings are unique.
Specifically, Lifeline stem cell creams are the only products in the world that contain human, non-embryonic stem cell extracts. This is possible because of ISCO’s development of parthenogenesis, the ability to generate true pluripotent stem cells without the use of a fertilized human embryo. It’s a one-of-a-kind technology that not only avoids the ethical issues common to stem cell application, but also results in stem cells that can be immune-matched to millions of people, avoiding the use of immuno-suppression drugs. ISCO scientists are focused on using these stem cells to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells.
Lifeline skin care is focused on the application of this technology to skin rejuvenation, combining stem cell biology, nanotechnology, and skin cream formulation technology to produce the highest quality, scientifically tested, and most effective anti-aging products available. The company does not license the brand name, the technology, the stem cell extracts, or proprietary ingredients to any other company. Moreover, revenues from Lifeline Skin Care help fund stem cell research for curing regenerative diseases like diabetes and Parkinson’s Disease.
However, to end users, the real life effectiveness of the product is most important, and is backed up by an independent clinical study showing 63% improved skin tone and brightness, 67% decreased wrinkles appearance, 73% increased skin elasticity, and 93% improved skin hydration.
For additional information, visit www.InternationalStemCell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Specifically, Lifeline stem cell creams are the only products in the world that contain human, non-embryonic stem cell extracts. This is possible because of ISCO’s development of parthenogenesis, the ability to generate true pluripotent stem cells without the use of a fertilized human embryo. It’s a one-of-a-kind technology that not only avoids the ethical issues common to stem cell application, but also results in stem cells that can be immune-matched to millions of people, avoiding the use of immuno-suppression drugs. ISCO scientists are focused on using these stem cells to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells.
Lifeline skin care is focused on the application of this technology to skin rejuvenation, combining stem cell biology, nanotechnology, and skin cream formulation technology to produce the highest quality, scientifically tested, and most effective anti-aging products available. The company does not license the brand name, the technology, the stem cell extracts, or proprietary ingredients to any other company. Moreover, revenues from Lifeline Skin Care help fund stem cell research for curing regenerative diseases like diabetes and Parkinson’s Disease.
However, to end users, the real life effectiveness of the product is most important, and is backed up by an independent clinical study showing 63% improved skin tone and brightness, 67% decreased wrinkles appearance, 73% increased skin elasticity, and 93% improved skin hydration.
For additional information, visit www.InternationalStemCell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
LaserLock Technologies, Inc. (LLTI) Voices its Solution on Pharmaceutical Counterfeit to Congress
LaserLock Technologies, a provider of authentication solutions to governments, healthcare providers, high-end retailers, and the gaming industry, recently submitted health-focused testimony to the U.S. House of Representatives Subcommittee during a hearing on “Securing our Nation’s Prescription Drug Supply Chain.”
In its testimony, LaserLock addressed Congress’ focus on anti-counterfeiting measures in the growing counterfeit pharmaceutical trade. The company’s proposed solution is an “innovative supply chain” that integrates the ubiquity of mobile devices, high-tech optics, secure anti-counterfeiting technologies, and the development of authentication databases as a secure means to track and trace prescription drugs.
“We are pleased that the United States Congress is taking seriously the threat counterfeit drugs pose to the American people,” Neil Alpert, president of LaserLock stated in the press release. “We believe it is critical that government, the healthcare industry and authentication providers work together to solve this problem. Our authentication system (Characteristic Verification System) is uniquely positioned to provide this kind of service.”
The proposed legislation calls for the U.S. Food and Drug Administration to oversee a serialization program responsible for tracking and tracing pharmaceuticals, and then collecting and storing data about each lot’s movements throughout the supply chain.
“As a veteran of both government service and the pharmaceutical industry, creating a national track and trace system presents an opportunity for the public and private sectors to solve a dangerous and expanding problem,” said Michael Sonnenreich, chairman of the board. “LaserLock is uniquely positioned to play a leadership role in designing such a system.”
For more information visit www.laserlocktech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
In its testimony, LaserLock addressed Congress’ focus on anti-counterfeiting measures in the growing counterfeit pharmaceutical trade. The company’s proposed solution is an “innovative supply chain” that integrates the ubiquity of mobile devices, high-tech optics, secure anti-counterfeiting technologies, and the development of authentication databases as a secure means to track and trace prescription drugs.
“We are pleased that the United States Congress is taking seriously the threat counterfeit drugs pose to the American people,” Neil Alpert, president of LaserLock stated in the press release. “We believe it is critical that government, the healthcare industry and authentication providers work together to solve this problem. Our authentication system (Characteristic Verification System) is uniquely positioned to provide this kind of service.”
The proposed legislation calls for the U.S. Food and Drug Administration to oversee a serialization program responsible for tracking and tracing pharmaceuticals, and then collecting and storing data about each lot’s movements throughout the supply chain.
“As a veteran of both government service and the pharmaceutical industry, creating a national track and trace system presents an opportunity for the public and private sectors to solve a dangerous and expanding problem,” said Michael Sonnenreich, chairman of the board. “LaserLock is uniquely positioned to play a leadership role in designing such a system.”
For more information visit www.laserlocktech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Advaxis, Inc. (ADXS) Encouraged by Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study
Advaxis, a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases, today told investors of encouraging preliminary data from the Phase 1 dose escalation study evaluating the safety of ADXS-cHER2 in companion dogs with Her2/neu overexpressing canine osteosarcoma being conducted at the University of Pennsylvania School of Veterinary Medicine.
The primary goal of the study is to establish the maximum tolerated dose of ADXS-cHER2. Preliminary data from the first two dose groups (3 dogs each) show that ADXS-cHER2 at either 1 x 10(8) or 5 x 10(8) cfu is well-tolerated. 100% of dogs experienced 1 or more mild (Grade 1) side effects consistent with cytokine release syndrome observed at the time of administration (fever, increased blood pressure, malaise, nausea, and/or vomiting). Early data also suggest that Her2/neu expression in canine osteosarcoma may denote a more aggressive phenotype.
The study is also being used to determine progression-free survival and overall survival. Early results from the first two dose groups (6 dogs) show a significant survival advantage in dogs that received ADXS-cHER2 compared to 6 dogs whose owners elected not to participate in the trial but who were followed for survival (p=0.01).
Dr. Nicola Mason, lead investigator in the Penn canine osteosarcoma study, plans to expand the trial to three additional sites in the United States. ADXS-cHER2 booster vaccinations will be given to evaluate the effects of maintenance immunotherapy.
“The preliminary data from this study are encouraging,” stated Dr. Nicola Mason. “The dogs that have been treated with ADXS-cHER2 are doing very well and although the numbers of vaccinated dogs are small, they do appear to be doing better than dogs with Her2/neu overexpressing tumors that did not receive the vaccine. I am extremely excited to expand this trial, make the vaccine available to more dogs, and determine its therapeutic benefit in dogs with this highly aggressive tumor type.”
“These preliminary findings suggest that the second Advaxis immunotherapy to be evaluated in a clinical setting (in addition to ADXS-HPV) may also improve survival in cancer. Furthermore, a veterinary oncology indication could potentially open an entirely new market for Advaxis Lm-LLO immunotherapies and further validates the versatility of our technology platform and constructs,” commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis.
For more information, visit www.Advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The primary goal of the study is to establish the maximum tolerated dose of ADXS-cHER2. Preliminary data from the first two dose groups (3 dogs each) show that ADXS-cHER2 at either 1 x 10(8) or 5 x 10(8) cfu is well-tolerated. 100% of dogs experienced 1 or more mild (Grade 1) side effects consistent with cytokine release syndrome observed at the time of administration (fever, increased blood pressure, malaise, nausea, and/or vomiting). Early data also suggest that Her2/neu expression in canine osteosarcoma may denote a more aggressive phenotype.
The study is also being used to determine progression-free survival and overall survival. Early results from the first two dose groups (6 dogs) show a significant survival advantage in dogs that received ADXS-cHER2 compared to 6 dogs whose owners elected not to participate in the trial but who were followed for survival (p=0.01).
Dr. Nicola Mason, lead investigator in the Penn canine osteosarcoma study, plans to expand the trial to three additional sites in the United States. ADXS-cHER2 booster vaccinations will be given to evaluate the effects of maintenance immunotherapy.
“The preliminary data from this study are encouraging,” stated Dr. Nicola Mason. “The dogs that have been treated with ADXS-cHER2 are doing very well and although the numbers of vaccinated dogs are small, they do appear to be doing better than dogs with Her2/neu overexpressing tumors that did not receive the vaccine. I am extremely excited to expand this trial, make the vaccine available to more dogs, and determine its therapeutic benefit in dogs with this highly aggressive tumor type.”
“These preliminary findings suggest that the second Advaxis immunotherapy to be evaluated in a clinical setting (in addition to ADXS-HPV) may also improve survival in cancer. Furthermore, a veterinary oncology indication could potentially open an entirely new market for Advaxis Lm-LLO immunotherapies and further validates the versatility of our technology platform and constructs,” commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis.
For more information, visit www.Advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Cardium Therapeutics, Inc. (CXM) Looks to Future with Three-Stage Growth Plan
Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in several markets, much like a rocket with multiple stages timed for continuous acceleration.
Immediate revenue is provided through Cardium’s To Go Brands subsidiary, acquired in 2012, which markets and sells a growing portfolio of over 25 healthy lifestyle products, including nutraceutical powder mixes and supplements designed for both convenience and health of active lifestyle consumers. Their product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements. It’s a big and fast growing market, projected by some to top $200 billion over the next several years, and should continue to provide Cardium with an important source of revenue to support their other developments.
Further down the timeline, but not too far, is Excellagen, Cardium’s FDA-cleared wound treatment gel that has already been proven to significantly aid healing for many types of wounds, including diabetic foot ulcers. The company is in the final commercialization stages for Excellagen, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations. The ease of use and effectiveness of this new treatment, together with the fact that it has broad application potential, bodes well for future revenue.
And finally there is Generx, an important DNA-based angiogenic growth factor therapeutic, designed to actively increase blood flow around the heart for the treatment of heart disease. The product is qualitatively different than traditional drugs for treating heart disease, drugs which only address the pain or future blockages. It is still under development, but Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods.
For additional information, visit www.CardiumTHX.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Immediate revenue is provided through Cardium’s To Go Brands subsidiary, acquired in 2012, which markets and sells a growing portfolio of over 25 healthy lifestyle products, including nutraceutical powder mixes and supplements designed for both convenience and health of active lifestyle consumers. Their product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements. It’s a big and fast growing market, projected by some to top $200 billion over the next several years, and should continue to provide Cardium with an important source of revenue to support their other developments.
Further down the timeline, but not too far, is Excellagen, Cardium’s FDA-cleared wound treatment gel that has already been proven to significantly aid healing for many types of wounds, including diabetic foot ulcers. The company is in the final commercialization stages for Excellagen, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations. The ease of use and effectiveness of this new treatment, together with the fact that it has broad application potential, bodes well for future revenue.
And finally there is Generx, an important DNA-based angiogenic growth factor therapeutic, designed to actively increase blood flow around the heart for the treatment of heart disease. The product is qualitatively different than traditional drugs for treating heart disease, drugs which only address the pain or future blockages. It is still under development, but Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods.
For additional information, visit www.CardiumTHX.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Jason Angelos of Accenture to Keynote at CallidusCloud (CALD) Connection’s Conference C3
Leading provider of hiring solutions, smart selling, and cloud software Callidus Software announced Friday that a managing director of Accenture Sales & Customer Services, Jason Angelos, will deliver a keynote address at the Aria Resort in Las Vegas, Nevada. The address will take place at CallidusCloud’s annual customer conference C3 2013, which is currently scheduled to run May 5-7, 2013.
A contributor to “Selling Through Someone Else: How to Use Agile Sales Networks and Partners to Sell More,” Angelos will discuss the training needed for developing a flexible sales staff and organization. Some of his focuses include optimizing individual sales performance, training, and overall execution using the cloud. C3 will also feature a remarkable industry-leading lineup of speakers, sponsors, and industry experts.
“C3 is the destination Sales and Marketing event of the year and the largest of its kind focusing on the real issues facing businesses in the new economy, and will see an unprecedented gathering of the industry’s top thought leaders and practitioners,” stated Rory Cameron, Senior Vice President, Corporate Development and Alliances, CallidusCloud. “We are pleased to team with Accenture to help our customers take advantage of cloud and mobile technology in order to maximize sales and marketing effectiveness.”
CallidusCloud Connection’s conference C3 is the premier destination for bringing together industry analysts, innovators, and leaders to learn how to transform organizations with the latest cloud, social and mobile technologies.
Callidus Software enables organizations to push performance and productivity across their business with its hiring, learning, marketing, and selling clouds. Small businesses to large enterprises across multiple industries and channels rely on CallidusCloud for quicker hiring, simpler learning, better marketing, and smarter selling.
For more information, visit www.calliduscloud.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Bridgeline Digital, Inc. (BLIN) Receives 15 Horizon Interactive Awards
Bridgeline Digital announced recently that the company had received fifteen 2013 Horizon Interactive Awards for outstanding development of interactive web applications and websites. This year’s 11th competition, with more than 1,000 entries from over 25 countries, evaluated categories ranging from online advertising to mobile applications.
Based in Burlington, MA, Bridgeline Digital is focused on helping online marketers realize the maximum potential of their online presence through improving websites, intranets, and online stores with Bridgeline’s iAPPS platform. iAPPS integrates Web Content Management, eCommerce, eMarketing, and Web Analytics; Bridgeline also provides end-to-end Digital Engagement solutions. Bridgeline has nine locations in the US and an Asia Pacific headquarters in Bangalore, India.
The company received awards for site development across a wide array of industries, such as Healthcare, Franchising, Financial Services, Pharmaceuticals, and Associations. Each of the winning websites was developed using iAPPS; the list of winning websites (from gold through bronze) included AARP International, Children’s Hospital Colorado Orthopedics, YMCA Retirement Fund, and American Psychiatric Association, among others.
Mike Sauce, Founder of the Horizon Interactive Awards, said, “The 2012 competition has, once again, raised the bar for future competitions. I can speak for the Judges by saying that we all were very impressed by the quality of the digital solutions by all of the entrants this year. There really seems to be a convergence of all forms of media providing rich user experiences with a renewed focus on sound marketing and design principles that clearly communicate a message. With fierce competition from all of the categories, this year’s winners should be proud to be among the best of the best from around the world.”
For more information, visit www.bridgelinedigital.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Based in Burlington, MA, Bridgeline Digital is focused on helping online marketers realize the maximum potential of their online presence through improving websites, intranets, and online stores with Bridgeline’s iAPPS platform. iAPPS integrates Web Content Management, eCommerce, eMarketing, and Web Analytics; Bridgeline also provides end-to-end Digital Engagement solutions. Bridgeline has nine locations in the US and an Asia Pacific headquarters in Bangalore, India.
The company received awards for site development across a wide array of industries, such as Healthcare, Franchising, Financial Services, Pharmaceuticals, and Associations. Each of the winning websites was developed using iAPPS; the list of winning websites (from gold through bronze) included AARP International, Children’s Hospital Colorado Orthopedics, YMCA Retirement Fund, and American Psychiatric Association, among others.
Mike Sauce, Founder of the Horizon Interactive Awards, said, “The 2012 competition has, once again, raised the bar for future competitions. I can speak for the Judges by saying that we all were very impressed by the quality of the digital solutions by all of the entrants this year. There really seems to be a convergence of all forms of media providing rich user experiences with a renewed focus on sound marketing and design principles that clearly communicate a message. With fierce competition from all of the categories, this year’s winners should be proud to be among the best of the best from around the world.”
For more information, visit www.bridgelinedigital.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, April 26, 2013
Low Carbon Technologies (LWCTF) is “One to Watch”
Low Carbon Technologies International is a U.S. based diversified clean-tech holding company focused on the clean-tech, construction, energy, environmental, mining, and real estate sectors. The company’s primary focus is on generating consistent shareholder growth by minimizing expenses and increasing asset values through leveraged acquisitions.
In addition to acquiring profitable companies, LWCTF’s business strategy includes the use of its various technologies in the development of clean-tech projects which are generally located on the company’s real estate assets. As an additional source of revenue, LWCTF also issues sub-licenses to third parties in exchange for a fair amount of project equity and licensing royalties.
To date, LWCTF has acquired 20 clean-tech technologies focused on the following segments: biofuels & chemicals, biomass, energy efficiency, energy storage, environmental mitigation bank, green building, LED lighting, solar, solar desalination, transportation, waste-to-energy, and water. According to a third party appraisal by Marshall & Stevens, the company’s technologies are currently valuated at approximately $142 million.
LWCTF’s management team has accumulated extensive experience in the carbon sector and is well supported by a board of directors comprised of individuals with a wealth of knowledge within the company’s primary sectors of clean-tech operations. The business strategy executed by these professionals has been highly profitable with LWCTF on track to generate upwards of $28 million in EBITDA for fiscal 2013.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
In addition to acquiring profitable companies, LWCTF’s business strategy includes the use of its various technologies in the development of clean-tech projects which are generally located on the company’s real estate assets. As an additional source of revenue, LWCTF also issues sub-licenses to third parties in exchange for a fair amount of project equity and licensing royalties.
To date, LWCTF has acquired 20 clean-tech technologies focused on the following segments: biofuels & chemicals, biomass, energy efficiency, energy storage, environmental mitigation bank, green building, LED lighting, solar, solar desalination, transportation, waste-to-energy, and water. According to a third party appraisal by Marshall & Stevens, the company’s technologies are currently valuated at approximately $142 million.
LWCTF’s management team has accumulated extensive experience in the carbon sector and is well supported by a board of directors comprised of individuals with a wealth of knowledge within the company’s primary sectors of clean-tech operations. The business strategy executed by these professionals has been highly profitable with LWCTF on track to generate upwards of $28 million in EBITDA for fiscal 2013.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Green Technology Solutions, Inc. (GTSO) Chilerecicla Partnership Would Tap Into and Leverage Burgeoning Global E-Waste Supplier Network
Green Technology Solutions, the aggressive young company which has made a name for itself by attacking the resource equation from both the mining and recycling sides, hunting for rare earths and precious minerals with the drill and via the landfill, reported progress today in their continued negotiations (aimed at striking a definitive agreement) with Chilean recycler, Chilerecicla, who is putting together a network of e-waste suppliers in Latin America.
This network would pump out valuable minerals for direct sale to overseas smelting markets and represents a huge win for Chilerecicla, who will be able to lock in favorable prices from e-waste suppliers, resulting in a healthy profit margin. Urban mining as it’s called will become an increasingly important part of the overall resource sector moving forward, as a rising percentage of total inputs are derived from recycled sources. This fact is the primary reason GTSO is positioning itself now for a leadership role in this burgeoning industry.
CEO of GTSO, Paul Watson, praised the business model Chilerecicla has developed and asserted to investors that the company was dead set on striking a partnership deal ahead of Chilerecicla breaking out as a major new player on the urban mining scene. Watson projected clear signals that GTSO is working very hard to secure an agreement whereby the company will help Chilerecicla expand operationally and in exchange receive both the vital industry contacts and best practices know-how required to emulate their model state side.
The goal will be to apply gleaned expertise from the Chilerecicla relationship as time progresses, honing in on the best ways to isolate e-waste before it ever gets to a landfill. This capacity, in combination with prevailing domestic legislative measures, will place GTSO in the pole position for turning landfill-bound e-trash into cold hard cash, as well as bottom line growth for their shareholders.
GTSO is intent on growing into a firm that can compete alongside major sector players like Industrial Services of America (IDSA) and Sims Metal Management (SMS), looking to springboard off the acquisition of Global Cell Buyers late last year, which was quickly re-branded by GTSO as Green Urban Mining in order to enhance focus of recycling/resale operations. This deal with Chilerecicla would be a big step towards realization of the company’s domestic urban mining strategy, stripping highly valuable elements such as gold, lithium, neodymium, and palladium from discarded electronics, helping to save the environment while tapping into a blossoming growth industry.
For more info on Green Technology Solutions, check out www.GTSOresources.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
This network would pump out valuable minerals for direct sale to overseas smelting markets and represents a huge win for Chilerecicla, who will be able to lock in favorable prices from e-waste suppliers, resulting in a healthy profit margin. Urban mining as it’s called will become an increasingly important part of the overall resource sector moving forward, as a rising percentage of total inputs are derived from recycled sources. This fact is the primary reason GTSO is positioning itself now for a leadership role in this burgeoning industry.
CEO of GTSO, Paul Watson, praised the business model Chilerecicla has developed and asserted to investors that the company was dead set on striking a partnership deal ahead of Chilerecicla breaking out as a major new player on the urban mining scene. Watson projected clear signals that GTSO is working very hard to secure an agreement whereby the company will help Chilerecicla expand operationally and in exchange receive both the vital industry contacts and best practices know-how required to emulate their model state side.
The goal will be to apply gleaned expertise from the Chilerecicla relationship as time progresses, honing in on the best ways to isolate e-waste before it ever gets to a landfill. This capacity, in combination with prevailing domestic legislative measures, will place GTSO in the pole position for turning landfill-bound e-trash into cold hard cash, as well as bottom line growth for their shareholders.
GTSO is intent on growing into a firm that can compete alongside major sector players like Industrial Services of America (IDSA) and Sims Metal Management (SMS), looking to springboard off the acquisition of Global Cell Buyers late last year, which was quickly re-branded by GTSO as Green Urban Mining in order to enhance focus of recycling/resale operations. This deal with Chilerecicla would be a big step towards realization of the company’s domestic urban mining strategy, stripping highly valuable elements such as gold, lithium, neodymium, and palladium from discarded electronics, helping to save the environment while tapping into a blossoming growth industry.
For more info on Green Technology Solutions, check out www.GTSOresources.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Tower Hill Mines Ltd. (THM) Video Chart for Friday, April 26, 2013
THM dropped a long-legged doji on Wednesday and then followed that signal of indecision with a 7 percent gain. Combined, the two days could be signaling a trend shift in the making for the chart.
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Ampio Pharmaceuticals, Inc. (AMPE) Announces Enrollment Completion for Run-In SPRING Study of Ampion in Osteoarthritis of the Knee
Development-stage biopharmaceutical company Ampio Pharmaceuticals announced it has completed patient enrollment for a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion for the treatment of moderate to severe osteoarthritis of the knee. It is anticipated that 12-week primary endpoint data will be available in the third quarter of 2013.
Ampion is being evaluated in the SPRING trial for its pain-reducing effect as a single intra-articular injection into the knee in 4 mL and 10 mL volumes, as compared with placebo at 12 weeks. More than the targeted 320 patients have been enrolled in the study, which is part of the U.S. development program for Ampion. The study was designed as a run-in to a Phase III pivotal trial, which the company will initiate as soon as the optimal volume is determined and the proposed pivotal trial is properly powered to meet its scientific objectives.
Ampio set very stringent site criteria to optimize the rate of enrollment in SPRING, and the company is pleased with the speed at which patient enrollment was completed. The company believes this trial can potentially show the inadequacies of current therapeutics in meeting the needs of osteoarthritis sufferers.
Ampion, the product being studied, is a non-steroidal anti-inflammatory biologic with the potential to be utilized in a wide variety of inflammatory conditions and autoimmune diseases. Ampion is protected by composition of matter, use, and synthetic form patents. Active ingredient aspartyl-alanyl diketopiperazine, or DA-DKP, is derived from two amino acids from human albumin and appears to have a significant role in the homeostasis of inflammation. The company has published various studies and articles about the anti-inflammatory activity of DA-DKP.
For more information, visit www.ampiopharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Ampion is being evaluated in the SPRING trial for its pain-reducing effect as a single intra-articular injection into the knee in 4 mL and 10 mL volumes, as compared with placebo at 12 weeks. More than the targeted 320 patients have been enrolled in the study, which is part of the U.S. development program for Ampion. The study was designed as a run-in to a Phase III pivotal trial, which the company will initiate as soon as the optimal volume is determined and the proposed pivotal trial is properly powered to meet its scientific objectives.
Ampio set very stringent site criteria to optimize the rate of enrollment in SPRING, and the company is pleased with the speed at which patient enrollment was completed. The company believes this trial can potentially show the inadequacies of current therapeutics in meeting the needs of osteoarthritis sufferers.
Ampion, the product being studied, is a non-steroidal anti-inflammatory biologic with the potential to be utilized in a wide variety of inflammatory conditions and autoimmune diseases. Ampion is protected by composition of matter, use, and synthetic form patents. Active ingredient aspartyl-alanyl diketopiperazine, or DA-DKP, is derived from two amino acids from human albumin and appears to have a significant role in the homeostasis of inflammation. The company has published various studies and articles about the anti-inflammatory activity of DA-DKP.
For more information, visit www.ampiopharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Mimvi, Inc. (MIMV) Launches Small Business App Development Service
Based out of California, leading mobile search and recommendation company Mimvi announced the launch of MimviApps today. MimviApps aims to deliver high-quality apps to the local and small business market at a fraction of the cost of custom development.
Offering three packages, the most popular being the native iPhone, iPad, and Android apps, with a mobile website for $999. Mimvi is also offering a $500 coupon for the first 60 days, bringing the initial setup price down by almost half.
“Apps are the new websites,” said Mimvi CEO Michael Poutre. “Virtually every business will need to have an app, and we see an opportunity to help millions of small and local companies get into Apple’s App Store as well as Google Play with our new program.”
MimviApps falls under Mimvi’s ‘LaunchPad’ business unit, which recently secured a major six-figure revenue deal with an unnamed company.
“Every LaunchPad and MimviApps customer will be a candidate for our core business around app discovery,” Poutre added. “Once we build them an app, we hope they’ll turn to us to help it get discovered.”
For more information, visit www.mimviapps.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Offering three packages, the most popular being the native iPhone, iPad, and Android apps, with a mobile website for $999. Mimvi is also offering a $500 coupon for the first 60 days, bringing the initial setup price down by almost half.
“Apps are the new websites,” said Mimvi CEO Michael Poutre. “Virtually every business will need to have an app, and we see an opportunity to help millions of small and local companies get into Apple’s App Store as well as Google Play with our new program.”
MimviApps falls under Mimvi’s ‘LaunchPad’ business unit, which recently secured a major six-figure revenue deal with an unnamed company.
“Every LaunchPad and MimviApps customer will be a candidate for our core business around app discovery,” Poutre added. “Once we build them an app, we hope they’ll turn to us to help it get discovered.”
For more information, visit www.mimviapps.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Curis, Inc. (CRIS) Receives Conditional Approval Recommendation for Erivedge from CHMP
Oncology-focused company Curis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional approval of Erivedge (vismodegib) for treating adult patients with symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is not appropriate for surgery or radiotherapy. Receiving conditional approval would make Erivedge Europe’s first licensed treatment for patients with advanced basal cell carcinoma, which is a rare form of skin cancer that can be disfiguring, debilitating, and even fatal.
“We are extremely pleased that the CHMP has recommended the conditional approval of Erivedge in the EU and we hope that this important medicine will soon be available to patients in Europe,” said Curis CEO Dan Passeri. “We continue to be pleased by the strength of Roche’s global regulatory and commercialization efforts regarding Erivedge, which we anticipate will significantly broaden patient access to Erivedge globally. Erivedge is currently under review for approval by health authorities in several countries outside of Europe, and regulatory submissions are planned in many additional countries. We view Roche’s broad efforts to expand patient access to Erivedge as a testament to its commitment to this important, first-in-class molecule.”
Possessing the authority to approve medicines for use in the European Union, the European Commission generally delivers final decisions within three months of the CHMP recommendation. The final decision will apply to all 27 member states of the EU. A conditional approval from the European Commission would mean a $6 million milestone payment for Curis from Genentech, which is a member of the Roche Group. The Roche Group is responsible for the commercialization of Erivedge in the EU.
Based on quality, safety, and submitted efficacy data, the CHMP stated it considers there to be a favorable benefit-to-risk balance for Erivedge and, therefore, recommended the granting of marketing authorization, which is conditional and will require submission of additional data from ongoing studies. The CHMP grants conditional approval for medicinal products that fulfill an unmet medical need.
For more information, visit www.curis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“We are extremely pleased that the CHMP has recommended the conditional approval of Erivedge in the EU and we hope that this important medicine will soon be available to patients in Europe,” said Curis CEO Dan Passeri. “We continue to be pleased by the strength of Roche’s global regulatory and commercialization efforts regarding Erivedge, which we anticipate will significantly broaden patient access to Erivedge globally. Erivedge is currently under review for approval by health authorities in several countries outside of Europe, and regulatory submissions are planned in many additional countries. We view Roche’s broad efforts to expand patient access to Erivedge as a testament to its commitment to this important, first-in-class molecule.”
Possessing the authority to approve medicines for use in the European Union, the European Commission generally delivers final decisions within three months of the CHMP recommendation. The final decision will apply to all 27 member states of the EU. A conditional approval from the European Commission would mean a $6 million milestone payment for Curis from Genentech, which is a member of the Roche Group. The Roche Group is responsible for the commercialization of Erivedge in the EU.
Based on quality, safety, and submitted efficacy data, the CHMP stated it considers there to be a favorable benefit-to-risk balance for Erivedge and, therefore, recommended the granting of marketing authorization, which is conditional and will require submission of additional data from ongoing studies. The CHMP grants conditional approval for medicinal products that fulfill an unmet medical need.
For more information, visit www.curis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Velti Plc (VELT) & Bauer Media Group UK Announce Two-Year Exclusive Mobile Marketing Partnership
Velti, the premier provider of mobile marketing and advertising technology worldwide, and Bauer Media Group UK, owner of many of the most successful and influential radio in the United Kingdom, announced today that have entered into a two-year, exclusive mobile marketing partnership. The agreement between the two companies stipulates that the mobile interactivity, marketing, and promotions for Bauer’s 43 radio stations will be managed and maintained by Velti. This includes all mobile messaging for brands such as Magic 105.4, KISS, Clyde 1, Key103, Radio City, Wave105 and Kerrang.
This promising endeavor will support Bauer Media’s ongoing initiative to develop and grow its relationship with its audiences. Velti will focus on compliance and operational excellence while coordinating all of Bauer’s mobile messaging and interactivity. In addition, Velti will incur the development of new concepts designed to increase audience engagement and loyalty using data and customer relationship management (CRM) mechanics.
“Our aim is to develop closer relationships with our audience by providing mobile engagement opportunities and interactivity throughout our campaigns,” said Joanne Baldwin, Digital Commercial Director at Bauer Radio. “Our listeners expect the best from Bauer so we wanted to work with the best supplier in the market. Velti is a partner we can trust and rely upon to deliver these mobile marketing services while also guiding and advising us on how to best capitalize on technology advancements in the mobile and digital landscape.”
Rob Weisz, Vice President of Sales at Velti, said, “Velti has worked closely with Bauer to ensure a seamless implementation across the entire portfolio of mobile interactive services. After launching the existing interactive services, we are working with Bauer to optimise and develop elegant CRM and marketing mechanics using data generated from SMS interactivity, as well as our range of platforms and technologies. Bauer has great ambitions and is driven to push new and exciting initiatives. We look forward to helping Bauer and its portfolio of brands capitalise on emerging trends that can drive real consumer value.”
For further information, visit www.velti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
This promising endeavor will support Bauer Media’s ongoing initiative to develop and grow its relationship with its audiences. Velti will focus on compliance and operational excellence while coordinating all of Bauer’s mobile messaging and interactivity. In addition, Velti will incur the development of new concepts designed to increase audience engagement and loyalty using data and customer relationship management (CRM) mechanics.
“Our aim is to develop closer relationships with our audience by providing mobile engagement opportunities and interactivity throughout our campaigns,” said Joanne Baldwin, Digital Commercial Director at Bauer Radio. “Our listeners expect the best from Bauer so we wanted to work with the best supplier in the market. Velti is a partner we can trust and rely upon to deliver these mobile marketing services while also guiding and advising us on how to best capitalize on technology advancements in the mobile and digital landscape.”
Rob Weisz, Vice President of Sales at Velti, said, “Velti has worked closely with Bauer to ensure a seamless implementation across the entire portfolio of mobile interactive services. After launching the existing interactive services, we are working with Bauer to optimise and develop elegant CRM and marketing mechanics using data generated from SMS interactivity, as well as our range of platforms and technologies. Bauer has great ambitions and is driven to push new and exciting initiatives. We look forward to helping Bauer and its portfolio of brands capitalise on emerging trends that can drive real consumer value.”
For further information, visit www.velti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Catasys, Inc. (CATS) CEO Dr. Manejwala to Present at American Society of Medicine Conference
Catasys, a provider of specialized health management services for health insurers and employers, reports that company CEO Omar Manejwala, M.D., will deliver a presentation at the American Society of Addiction Medicine’s (ASAM) 44th annual medical-scientific conference, “New Treatments in Addiction Medicine,” held April 25 – 28, 2013, in Chicago.
ASAM is a professional society representing more than 3,000 physicians focused on enhancing access and quality of addiction treatment, as well as educating physicians and the public and supporting research and prevention.
Dr. Manejwala, who oversees medical affairs at Catasys, will highlight innovation in clinical improvements in substance dependent populations in a presentation entitled “Combining Predictive Analytics, Outreach, Evidence Based Treatment, Case Management and Monitoring to Generate Clinical Outcome Driven Cost Reductions in High Cost Substance Dependent Populations.”
Catasys’ focus on substance dependence is based on its OnTrakTM program, which was designed to improve member health while lowering costs by combining evidence-based medical and psychosocial interventions with care coaching in a 52-week outpatient program.
On Friday, April 26, Dr. Manejwala will present Catasys’ research and OnTrack™ program to attendees of this year’s ASAM.
For further information visit www.catasyshealth.com or www.asam.org
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
ASAM is a professional society representing more than 3,000 physicians focused on enhancing access and quality of addiction treatment, as well as educating physicians and the public and supporting research and prevention.
Dr. Manejwala, who oversees medical affairs at Catasys, will highlight innovation in clinical improvements in substance dependent populations in a presentation entitled “Combining Predictive Analytics, Outreach, Evidence Based Treatment, Case Management and Monitoring to Generate Clinical Outcome Driven Cost Reductions in High Cost Substance Dependent Populations.”
Catasys’ focus on substance dependence is based on its OnTrakTM program, which was designed to improve member health while lowering costs by combining evidence-based medical and psychosocial interventions with care coaching in a 52-week outpatient program.
On Friday, April 26, Dr. Manejwala will present Catasys’ research and OnTrack™ program to attendees of this year’s ASAM.
For further information visit www.catasyshealth.com or www.asam.org
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, April 25, 2013
Santo Mining Corp. (SANP) Survey of Charles Claim Yields 10.79 g/t Silver, Over 1.0% Copper
Santo Mining, who is doing some superb work in the Dominican Republic, reported news today out of their Charles Claim, as geochemical analysis of rock sampling comes back with 10.79 g/t silver and over 1% copper.
These are solid reads from the silver-copper rich host formation known as the Tireo and the results accentuate the prime geographical position of this claim nicely, lying as it does, smack next to Goldquest’s La Escandalosa claim (trenching results like 8.71 g/t gold over 91.8 feet). Work done a decade ago by Goldquest and Goldfields in the region led to kicking up their five-site, 22-mile long swathe of areas of heavy gold and copper mineralization (Romero, La Escandalosa and etc.), with the most recent work done in 2012 at La Escandalosa showing several bonanza grade intercepts as high as 847 feet grading 7.88 g/t Au and 1.43% Cu.
In this regional geologic context, especially considering the undeveloped nature of the lands, the rock sampling done by SANP looks cherry. Sample processing was handled by well-known Vancouver-based industry benchmarking firm, Acme Labs, who performed multi-element and fire-assay analysis. With these kinds of fresh reconnaissance survey results in hand, from just northeast of what is the biggest gold discovery in the Dominican Republic in two decades, shareholders at SANP are no doubt beaming with pride.
This comprehensive surveying effort of the 687-acre Charles site was begun back in March by the company’s ingeniously designed mobile strike team, headed up by Elpidio Moronta. The effort managed to capture quite a high-res portrait of the site’s mineral potential. Stream sediment sampling of the Rio Guayabo and Rio Piedra Blanca rivers/tributaries, combined with grab and outcrop samples, including ones from several key areas of the Rio Piedra Blanca river, have yielded a clear picture, with even the lower end of the spectrum offering quality grades.
President of SANP, Al French, told markets that the exploration team is already headed back out the door to Charles to do some more detailed sampling in the prospective zones identified by these survey results. French also explained that management was putting in some really late nights back at the company’s Santo Domingo offices, in order to quickly secure as many as four more claims clustered in the target area. These new claims are all around Goldquest’s bonanza claims and French indicated that SANP was looking at applying the recent (Mar 12) $16M commitment (an equity enhancement program designed to spur SANP’s aggressive exploration plans) from New York-based Magna Group affiliate, Hanover Holdings I, LLC, to development of the Charles.
For more information on Santo Mining, visit www.SantoMining.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
These are solid reads from the silver-copper rich host formation known as the Tireo and the results accentuate the prime geographical position of this claim nicely, lying as it does, smack next to Goldquest’s La Escandalosa claim (trenching results like 8.71 g/t gold over 91.8 feet). Work done a decade ago by Goldquest and Goldfields in the region led to kicking up their five-site, 22-mile long swathe of areas of heavy gold and copper mineralization (Romero, La Escandalosa and etc.), with the most recent work done in 2012 at La Escandalosa showing several bonanza grade intercepts as high as 847 feet grading 7.88 g/t Au and 1.43% Cu.
In this regional geologic context, especially considering the undeveloped nature of the lands, the rock sampling done by SANP looks cherry. Sample processing was handled by well-known Vancouver-based industry benchmarking firm, Acme Labs, who performed multi-element and fire-assay analysis. With these kinds of fresh reconnaissance survey results in hand, from just northeast of what is the biggest gold discovery in the Dominican Republic in two decades, shareholders at SANP are no doubt beaming with pride.
This comprehensive surveying effort of the 687-acre Charles site was begun back in March by the company’s ingeniously designed mobile strike team, headed up by Elpidio Moronta. The effort managed to capture quite a high-res portrait of the site’s mineral potential. Stream sediment sampling of the Rio Guayabo and Rio Piedra Blanca rivers/tributaries, combined with grab and outcrop samples, including ones from several key areas of the Rio Piedra Blanca river, have yielded a clear picture, with even the lower end of the spectrum offering quality grades.
President of SANP, Al French, told markets that the exploration team is already headed back out the door to Charles to do some more detailed sampling in the prospective zones identified by these survey results. French also explained that management was putting in some really late nights back at the company’s Santo Domingo offices, in order to quickly secure as many as four more claims clustered in the target area. These new claims are all around Goldquest’s bonanza claims and French indicated that SANP was looking at applying the recent (Mar 12) $16M commitment (an equity enhancement program designed to spur SANP’s aggressive exploration plans) from New York-based Magna Group affiliate, Hanover Holdings I, LLC, to development of the Charles.
For more information on Santo Mining, visit www.SantoMining.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Sibling Group Holdings, Inc. (SIBE) Takes Advantage of Changing Educational Landscape and Taps into Expanded Opportunities
Sibling Group Holdings, a company focused on enhancing and accelerating the delivery of 21st century learning, today announced its plan to open an operation in Atlanta to provide teacher certifications in a number of key areas. The initial focus will be on the teacher requirements for the Pre-K market, where a rising number of states are mandating a range of certifications from teachers.
“We see the need for certification and credentialing services growing as the education industry transforms from traditional school systems to reflect more independent, private, charter and corporate education oriented entities,” stated Neal Sessions, Chairman of Sibling. He continued, “While we will begin in Atlanta with the Pre-K requirements, we expect certification programs to grow to include other geographic regions and specialties such as ESL/ELL and certain STEM course areas.”
Most states have a number of options for pre-K teacher requirements. These options may include a stated number of hours in post-secondary education in child development or early childhood education, a Child Development Associate (CDA) certification, or a diploma as a child development technician. There are several teacher certifications that some states list as acceptable for part or all of the teacher requirements in licensed daycare facilities. Sibling Group will pursue fully accreditation through the International Association for Continuing Education and Training (IACET), and other accreditation organizations, as it expands its course offerings.
The national certification for Pre-K teachers is the Child Development Associate (CDA). Available through the Council for Professional Recognition, the CDA is included by all states but one as part of their regulations for licensing childcare facilities. Experience and training are both included in eligibility requirements. Within the five years preceding the application, teachers must have worked with children for 480 hours. During that time they must also have had 120 clock hours of approved courses in child care education. In addition to passing the required courses, initial certification requires documentation of the applicant’s competence and observation of the teacher in the classroom setting. Following the observation, the applicant is interviewed. The initial certification is good for three years, renewals for five years. In addition to a current First Aid Certification, renewal requirements include 45 clock hours of training (4.5 continuing education units).
For more information on Sibling Group Holdings, visit www.newco4education.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“We see the need for certification and credentialing services growing as the education industry transforms from traditional school systems to reflect more independent, private, charter and corporate education oriented entities,” stated Neal Sessions, Chairman of Sibling. He continued, “While we will begin in Atlanta with the Pre-K requirements, we expect certification programs to grow to include other geographic regions and specialties such as ESL/ELL and certain STEM course areas.”
Most states have a number of options for pre-K teacher requirements. These options may include a stated number of hours in post-secondary education in child development or early childhood education, a Child Development Associate (CDA) certification, or a diploma as a child development technician. There are several teacher certifications that some states list as acceptable for part or all of the teacher requirements in licensed daycare facilities. Sibling Group will pursue fully accreditation through the International Association for Continuing Education and Training (IACET), and other accreditation organizations, as it expands its course offerings.
The national certification for Pre-K teachers is the Child Development Associate (CDA). Available through the Council for Professional Recognition, the CDA is included by all states but one as part of their regulations for licensing childcare facilities. Experience and training are both included in eligibility requirements. Within the five years preceding the application, teachers must have worked with children for 480 hours. During that time they must also have had 120 clock hours of approved courses in child care education. In addition to passing the required courses, initial certification requires documentation of the applicant’s competence and observation of the teacher in the classroom setting. Following the observation, the applicant is interviewed. The initial certification is good for three years, renewals for five years. In addition to a current First Aid Certification, renewal requirements include 45 clock hours of training (4.5 continuing education units).
For more information on Sibling Group Holdings, visit www.newco4education.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
GlobalWise Investments, Inc. (GWIV) Growth Continues to be Driven by Flexible Business Features
GlobalWise offers virtually every type of business or organization a comprehensive document management ECM (Enterprise Content Management) solution via its subsidiary Intellinetics. Actively supported applications include Accounts Payable, Education, Financial Services, Healthcare, Law Enforcement & Corrections, Law, Manufacturing & Distribution, Retail, Government, and Human Resources. Every version is oriented to individual organizational and industrial needs, but all have a set of industry-leading features that have been key to the company’s growth.
• Flexible Implementation, with hosted, premise-based, or cloud-based deployment options
• Viewing Flexibility, providing customized document indexing including barcode indexing, dynamic search and retrieval, online viewing for collaboration, and full worldwide online access
• Work Flow, allowing users to electronically review documents, conduct approvals, route content, assign work tasks, and enable audit trails
• Advanced Privacy Technology, allowing black-out of any sensitive content, user controlled redaction and automated redaction
• Host System Integration, with easy linkage to existing host applications to support dynamic database lookups and retrieval
• Records Management, helping users to manage both paper and electronic documents through long term archiving, automate document retention policies, and ensure any regulatory compliance
In particular, the company’s advanced cloud-based deployment option provides highly secure 24/7 access to critical organizational information from anywhere in the world. Cloud based computing continues to grow because it offers quantifiable documented economic and operational benefits, such as cost savings, faster time-to-value, superior compliance and disaster recovery, greater IT efficiency, and enhanced competitive positioning.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
GlobalWise Investments, Inc. (GWIV) Growth Continues to be Driven by Flexible Business Features
GlobalWise offers virtually every type of business or organization a comprehensive document management ECM (Enterprise Content Management) solution via its subsidiary Intellinetics. Actively supported applications include Accounts Payable, Education, Financial Services, Healthcare, Law Enforcement & Corrections, Law, Manufacturing & Distribution, Retail, Government, and Human Resources. Every version is oriented to individual organizational and industrial needs, but all have a set of industry-leading features that have been key to the company’s growth.
• Flexible Implementation, with hosted, premise-based, or cloud-based deployment options
• Viewing Flexibility, providing customized document indexing including barcode indexing, dynamic search and retrieval, online viewing for collaboration, and full worldwide online access
• Work Flow, allowing users to electronically review documents, conduct approvals, route content, assign work tasks, and enable audit trails
• Advanced Privacy Technology, allowing black-out of any sensitive content, user controlled redaction and automated redaction
• Host System Integration, with easy linkage to existing host applications to support dynamic database lookups and retrieval
• Records Management, helping users to manage both paper and electronic documents through long term archiving, automate document retention policies, and ensure any regulatory compliance
In particular, the company’s advanced cloud-based deployment option provides highly secure 24/7 access to critical organizational information from anywhere in the world. Cloud based computing continues to grow because it offers quantifiable documented economic and operational benefits, such as cost savings, faster time-to-value, superior compliance and disaster recovery, greater IT efficiency, and enhanced competitive positioning.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
• Flexible Implementation, with hosted, premise-based, or cloud-based deployment options
• Viewing Flexibility, providing customized document indexing including barcode indexing, dynamic search and retrieval, online viewing for collaboration, and full worldwide online access
• Work Flow, allowing users to electronically review documents, conduct approvals, route content, assign work tasks, and enable audit trails
• Advanced Privacy Technology, allowing black-out of any sensitive content, user controlled redaction and automated redaction
• Host System Integration, with easy linkage to existing host applications to support dynamic database lookups and retrieval
• Records Management, helping users to manage both paper and electronic documents through long term archiving, automate document retention policies, and ensure any regulatory compliance
In particular, the company’s advanced cloud-based deployment option provides highly secure 24/7 access to critical organizational information from anywhere in the world. Cloud based computing continues to grow because it offers quantifiable documented economic and operational benefits, such as cost savings, faster time-to-value, superior compliance and disaster recovery, greater IT efficiency, and enhanced competitive positioning.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
GlobalWise Investments, Inc. (GWIV) Growth Continues to be Driven by Flexible Business Features
GlobalWise offers virtually every type of business or organization a comprehensive document management ECM (Enterprise Content Management) solution via its subsidiary Intellinetics. Actively supported applications include Accounts Payable, Education, Financial Services, Healthcare, Law Enforcement & Corrections, Law, Manufacturing & Distribution, Retail, Government, and Human Resources. Every version is oriented to individual organizational and industrial needs, but all have a set of industry-leading features that have been key to the company’s growth.
• Flexible Implementation, with hosted, premise-based, or cloud-based deployment options
• Viewing Flexibility, providing customized document indexing including barcode indexing, dynamic search and retrieval, online viewing for collaboration, and full worldwide online access
• Work Flow, allowing users to electronically review documents, conduct approvals, route content, assign work tasks, and enable audit trails
• Advanced Privacy Technology, allowing black-out of any sensitive content, user controlled redaction and automated redaction
• Host System Integration, with easy linkage to existing host applications to support dynamic database lookups and retrieval
• Records Management, helping users to manage both paper and electronic documents through long term archiving, automate document retention policies, and ensure any regulatory compliance
In particular, the company’s advanced cloud-based deployment option provides highly secure 24/7 access to critical organizational information from anywhere in the world. Cloud based computing continues to grow because it offers quantifiable documented economic and operational benefits, such as cost savings, faster time-to-value, superior compliance and disaster recovery, greater IT efficiency, and enhanced competitive positioning.
For additional information on GlobalWise and its subsidiary, Intellinetics, visit www.GlobalWiseInvestments.com and www.Intellinetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Oculus Innovative Sciences, Inc. (OCLS) Receives Regulatory Approvals for Three New Microcyn-Based Products in the Middle East
Global healthcare company Oculus Innovative Sciences has announced two new regulatory approvals in Kuwait, Iraq, and Dubai for three new Microcyn-based consumer products. The three products – all of which are targeted to be launched in fall 2013 – are Face Cool, which is a hydrogel for treating acne and various dermatoses; Baby Cool, which is a hydrogel for treating baby rash; and Lady Cool, which is a feminine hygiene wash.
Oculus is pleased to broaden its product portfolio to include consumer products in these key Middle East countries. The company’s original Microcyn-based advanced wound management products have received acclaim from healthcare institutions throughout the region – many of which have reported a substantial decline in healthcare costs as a result of reduced infections, antibiotics, and hospitalization days. The data indicating these cost savings was used to support the regulatory filings for these latest consumer products.
“We are looking forward to the commercialization of these new and unique products this coming fall through our Dubai-based Microsafe Care Management subsidiary,” said Dr. Walid Yousef, vice president of Joseph & Gionis, which is Oculus’ master distributor in the Middle East.
Occulus, a worldwide healthcare company, is engaged in designing, manufacturing, and marketing prescription and nonprescription products in more than 20 countries. Oculus’ products are used to treat patients in surgical/advanced wound management, dermatology, women’s health, and animal health to address unmet medical needs in these markets – simultaneously raising the bar in patient care and lowering overall healthcare costs. Headquartered in Petaluma, Calif., Oculus has manufacturing operations in the U.S. and Latin America.
For more information, visit www.oculusis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Oculus is pleased to broaden its product portfolio to include consumer products in these key Middle East countries. The company’s original Microcyn-based advanced wound management products have received acclaim from healthcare institutions throughout the region – many of which have reported a substantial decline in healthcare costs as a result of reduced infections, antibiotics, and hospitalization days. The data indicating these cost savings was used to support the regulatory filings for these latest consumer products.
“We are looking forward to the commercialization of these new and unique products this coming fall through our Dubai-based Microsafe Care Management subsidiary,” said Dr. Walid Yousef, vice president of Joseph & Gionis, which is Oculus’ master distributor in the Middle East.
Occulus, a worldwide healthcare company, is engaged in designing, manufacturing, and marketing prescription and nonprescription products in more than 20 countries. Oculus’ products are used to treat patients in surgical/advanced wound management, dermatology, women’s health, and animal health to address unmet medical needs in these markets – simultaneously raising the bar in patient care and lowering overall healthcare costs. Headquartered in Petaluma, Calif., Oculus has manufacturing operations in the U.S. and Latin America.
For more information, visit www.oculusis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
